ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0499

Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires

John Pauling1, Lan Yu2, Christopher Denton3, Tracy Frech4, Ariane Herrick5, Laura Hummers6, Lesley Ann Saketkoo7, Ami Shah8, Dinesh Khanna9 and Robyn Domsic2, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Pittsburgh, Pittsburgh, PA, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 4University of Utah, Salt Lake City, UT, 5University of Manchester, Salford, United Kingdom, 6Johns Hopkins Univerisity, Baltimore, MD, 7University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, 8Johns Hopkins Rheumatology, Baltimore, MD, 9University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2021

Keywords: Biostatistics, Outcome measures, Patient reported outcomes, Raynaud's phenomenon, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)

Session Type: Abstract Session

Session Time: 4:15PM-4:30PM

Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome instrument devised to assess the severity and impact of SSc-RP. The ASRAP items are grounded in the patient experience of SSc-RP. We report the development and subsequent assessment of internal reliability and preliminary construct validity testing of long and short-form versions of the ASRAP questionnaire.

Methods: The international multicentre ASRAP validation study enrolled English speaking SSc-RP patients from UK and US scleroderma centres during 2 consecutive winters 2019-2021. All participants completed a 39-item ASRAP questionnaire. Item reduction, scale scoring and derivation of a short-form ASRAP were based upon item response theory (IRT) assumptions and calibrated using the graded response model. The final 27-item long-form scores were correlated with a 10-item short form scores using Pearson’s correlation. Once scales were devised, preliminary assessment of construct validity was determined by Pearson’s correlation between long and short-form ASRAP scores and a range of concurrent disease specific and legacy instruments capturing SSc-RP patient measures of disease activity/impact and relevant domains including cold sensitivity, pain, function and patient global health.

Results: A total of 438 SSc patients were enrolled at UK (n=238) and US (n=200) sites. A data driven approach with expert opinion was used to devise a 27-item long-form and 10-item short-form. Internal reliability between long and short form ASRAP questionnaires was excellent with Pearson correlation coefficient values of 0.976 (p< 0.0001). Evidence of construct validity of the long and short form ASRAP was indicated by strong agreement with existing global assessments of RP severity and impact (Scleroderma Health Assessment Questionnaire RP VAS and Patient RP global VAS (Figure 1). The short and long-form ASRAP questionnaire also had statistically significant correlations (in anticipated direction) with legacy instruments for assessing disability, hand function, pain and global health assessment (Figure 1).

Conclusion: Our preliminary analysis from the ASRAP validation study indicates strong internal reliability between long and putative short form ASRAP questionnaires. Cross-sectional psychometric analyses have indicated encouraging agreement with both global assessments of RP impact/severity and legacy instruments for assessing other relevant aspects of health pertinent to SSc. Further work to assess longitudinal reliability and sensitivity of change of the ASRAP questionnaire is planned.


Disclosures: J. Pauling, None; L. Yu, None; C. Denton, Acceleron, 2, 6, Actelion, 2, 6, Arxx Therapeutics, 2, 6, Boehringer Ingelheim, 2, 6, Bristol-Myers Squibb, 2, 6, Corbus, 2, 6, CSL Behring, 2, 6, Galapagos NV, 2, 6, GlaxoSmithKline, 2, 6, Horizon, 2, 6, Inventiva, 2, 6, Roche, 2, 6, Sanofi, 2, 6, Servier, 2; T. Frech, None; A. Herrick, None; L. Hummers, Boerhinger Ingelheim, 1, 5, Corbus Pharmaceuticals, 1, 5, Cumberland Pharmaceuticals, 5, Kadmon Corporation, 5, Medpace, 5; L. Saketkoo, None; A. Shah, None; D. Khanna, AbbVie, 2, Acceleron, 2, Actelion, 2, Amgen, 2, Bayer, 2, 5, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 5, CiviBioPharma/Eicos Sciences, Inc, 12, Leadership/Equity position (Chief Medical Officer), Corbus, 2, CSL Behring, 2, Eicos Sciences, Inc, 11, Galapagos NV, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon Therapeutics, 2, 5, Immune Tolerance Network, 5, Merck Sharp & Dohme, 2, Mitsubishi Tanabe Pharma, 2, National Institutes of Health, 5, Pfizer, 5, Sanofi-Aventis, 2, United Therapeutics, 2, Prometheus, 2, Theraly, 2, AstraZeneca, 2; R. Domsic, None.

To cite this abstract in AMA style:

Pauling J, Yu L, Denton C, Frech T, Herrick A, Hummers L, Saketkoo L, Shah A, Khanna D, Domsic R. Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/preliminary-assessment-of-internal-reliability-and-construct-validity-of-long-and-short-form-assessment-of-systemic-sclerosis-associated-raynauds-phenomenon-asrap-questionnaires/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preliminary-assessment-of-internal-reliability-and-construct-validity-of-long-and-short-form-assessment-of-systemic-sclerosis-associated-raynauds-phenomenon-asrap-questionnaires/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology